The consensus is to preserve this as a debated candidate, not a canonical world-model claim. Replication or rerun evidence should precede promotion into Atlas or market funding.
No AI visual card yet
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
2 citations0 with PMIDValidation: 0%1 supporting / 1 opposing
✓For(1)
No supporting evidence
No opposing evidence
(1)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
1
1
MECH 1CLIN 1GENE 0EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Concrete next test: cell-type-specific LRP1 pertur…
Supporting
CLIN
AD-MASTER-PLAN-…
-
-
-
-
-
Promotion before replication would weaken quality …
Opposing
MECH
AD-MASTER-PLAN-…
-
-
-
-
-
Legacy Card View — expandable citation cards
✓ Supporting Evidence
1
Concrete next test: cell-type-specific LRP1 perturbation with live tau uptake, trans-synaptic spread, and vasc…▼
Concrete next test: cell-type-specific LRP1 perturbation with live tau uptake, trans-synaptic spread, and vascular safety readouts
AD-MASTER-PLAN-LRP1-20260428030757
✗ Opposing Evidence
1
Promotion before replication would weaken quality control.
AD-MASTER-PLAN-LRP1-20260428030757
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-28 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Theorist position for analysis AD-MASTER-PLAN-LRP1-20260428030757: AD Master Plan preregistration: LRP1
Context: Preregistered claim: LRP1-mediated tau uptake disruption in neurons initiates the earliest tau propagation cascade; blocking LRP1 prevents downstream spreading
Primary claim: LRP1-mediated tau uptake disruption as an initiator of early tau propagation is a debate-worthy mechanism or quality claim, not just a restatement of the analysis title. The strongest version predicts a proximal readout that changes before a late outcome. For this AD master-plan preregistration, the debate sh
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Skeptic critique for analysis AD-MASTER-PLAN-LRP1-20260428030757: AD Master Plan preregistration: LRP1
The analysis question is substantive, but the current record does not by itself prove the claim. The main dissent is: LRP1 has broad vascular and lipid roles, so blocking uptake may trade tau reduction for impaired clearance or vascular toxicity.
The debate should reject overclaiming in three forms. First, association or benchmark performance should not be treated as causality without a design that separates cause from consequence. Second, a positive average effect can hide subgroup failure
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Domain expert assessment for analysis AD-MASTER-PLAN-LRP1-20260428030757: AD Master Plan preregistration: LRP1
The practical path is staged. Stage 1 should lock the data inputs, covariates, and endpoints. Stage 2 should run the most direct validation: cell-type-specific LRP1 perturbation with live tau uptake, trans-synaptic spread, and vascular safety readouts. Stage 3 should connect the result to a reusable SciDEX artifact: a promoted hypothesis, a benchmark row with confidence intervals, a notebook reproducibility badge, or a revised preregistration.
Feasibility is moderate because the que
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{ "ranked_hypotheses": [ { "title": "LRP1-mediated tau uptake disruption as an initiator of early tau propagation requires proximal validation", "description": "The debate supports carrying forward LRP1-mediated tau uptake disruption as an initiator of early tau propagation only if a proximal endpoint changes before the late outcome. The decisive validation path is: cell-type-specific LRP1 perturbation with live tau uptake, trans-synaptic spread, and vascular safety readouts.", "target_gene": "LRP1", "dimension_scores": { "evidence_strength": 0.57,
Price History
No price history recorded yet
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0000
Events (7d)
0
Clinical Trials (0)
No clinical trials data available
📚 Cited Papers (0)
No linked papers yet
📅 Citation Freshness Audit
Freshness score = exp(-age×ln2/5): halves every 5 years.
Green >0.6,
Amber 0.3–0.6,
Red <0.3.
No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.